Kerala Ayurveda

Which are the latest news on Kerala Ayurveda?

Why is Kerala Ayurveda Ltd falling/rising?

As of 05-Sep, Kerala Ayurveda Ltd's stock price is rising to Rs 181.50, up 4.97% and showing strong recent performance with a 10.84% gain over the past three days. Despite a year-to-date decline of 42.52%, the stock's current upward momentum and sector outperformance suggest positive trends.

As of 05-Sep, Kerala Ayurveda Ltd's stock price is rising, currently at Rs 181.50, reflecting an increase of Rs 8.6 or 4.97%. This upward movement is supported by a strong performance over the past three days, during which the stock has gained 10.84%. Additionally, it opened with a gain of 4.05% today and has outperformed its sector by 5.42%. <BR><BR>In the context of recent performance, the stock has shown a positive return of 1.65% over the past week, while the benchmark Sensex has declined by 0.97%. Over the past month, Kerala Ayurveda Ltd has experienced a significant rise of 16.35%, contrasting with a 2.44% drop in the Sensex. <BR><BR>Despite these positive trends, it is important to note that the stock has a year-to-date decline of 42.52% and a one-year decline of 60.84%. However, the recent gains and the stock's performance relative to the sector indicate a current upward momentum. The stock is trading above its 5-day, 20-day, and 50-day moving averages, although it remains below its 100-day and 200-day moving averages. <BR><BR>Overall, the combination of recent gains, positive sector performance, and a significant opening increase contributes to the rising stock price of Kerala Ayurveda Ltd.

Who are in the management team of Kerala Ayurveda?

The management team of Kerala Ayurveda includes Ramesh Vangal (Chairman), K Anilkumar (Whole-time Director), Anand Subramanian, Gokul Patnaik, and Harish Menon (Directors), along with independent directors S Krishnamurthy, Shilpa Kiran Gududur, and Rajesh Sharma, and Ashitha B R as Company Secretary. They oversee the company's operations and strategic direction.

The management team of Kerala Ayurveda includes the following individuals:<BR><BR>1. **Ramesh Vangal** - Chairman (Non-Executive)<BR>2. **K Anilkumar** - Whole-time Director<BR>3. **Anand Subramanian** - Director<BR>4. **Harish Menon** - Independent Director<BR>5. **Gokul Patnaik** - Director<BR>6. **S Krishnamurthy** - Independent Director<BR>7. **Ashitha B R** - Company Secretary & Compliance Officer<BR>8. **Shilpa Kiran Gududur** - Independent Director<BR>9. **Rajesh Sharma** - Independent Director<BR><BR>This team is responsible for overseeing the operations and strategic direction of the company.

What does Kerala Ayurveda do?

Kerala Ayurveda Ltd manufactures Ayurveda products and services, classified as a Micro Cap company with a market cap of INR 234 Cr. As of June 2026, it reported net sales of 33 Cr and a net loss of 8 Cr.

Overview: <BR>Kerala Ayurveda Ltd is engaged in the manufacture of Ayurveda products and services, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History: <BR>Kerala Ayurveda Ltd was established on 6th July 1992. The company has been involved in various activities related to Ayurveda and reported net sales and net profit for the quarter ending June 2026.<BR><BR>Financial Snapshot: <BR>- Most recent Net Sales: 33 Cr (Quarterly Results - Jun 2026) <BR>- Most recent Net Profit: -8 Cr (Quarterly Results - Jun 2026) <BR>- Market-cap value: INR 234 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>- P/E: N/A <BR>- Industry P/E: 37 <BR>- Dividend Yield: 0.00% <BR>- Debt Equity: 7.26 <BR>- Return on Equity: -148.92% <BR>- Price to Book: 20.92 <BR><BR>Contact Details: <BR>Address: VII/415 Nedumbassery, Athani P O Aluva Ernakulam Kerala : 683585 <BR>Tel: 91-484-2476301/2/3/4 <BR>Email: info@keralaayurveda.biz <BR>Website: http://www.keralaayurveda.biz

Who are the peers of the Kerala Ayurveda?

Kerala Ayurveda's peers include Zenotech Lab, Astonea Labs, Aarey Drugs, Lyka Labs, Nectar Lifesci, Natural Capsules, Sanjiv.Parant, Coral Labs, and Oxygenta Pharma. Among these, Astonea Labs shows the highest 1-year return at 57.61%, while Kerala Ayurveda has the lowest at -63.87%.

Peers: The peers of Kerala Ayurveda are Zenotech Lab., Astonea Labs, Aarey Drugs, Lyka Labs, Nectar Lifesci., Natural Capsules, Sanjiv.Parant., Coral Labs., and Oxygenta Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sanjiv.Parant. and Accretion Pha., while Average management risk is found at Zenotech Lab., Astonea Labs, Lyka Labs, Nectar Lifesci., and the rest. Below Average management risk is noted at Aarey Drugs, Kerala Ayurveda, Natural Capsules, Coral Labs., and Oxygenta Pharma. Good growth is seen at Astonea Labs and Sanjiv.Parant., while Below Average growth is present at Zenotech Lab., Aarey Drugs, Lyka Labs, Nectar Lifesci., Kerala Ayurveda, Natural Capsules, Coral Labs., and Oxygenta Pharma. Excellent capital structure is noted at Zenotech Lab. and Sanjiv.Parant., while Below Average capital structure is found at Astonea Labs, Aarey Drugs, Lyka Labs, Nectar Lifesci., Kerala Ayurveda, Natural Capsules, Coral Labs., and Oxygenta Pharma.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Astonea Labs at 57.61%, while Kerala Ayurveda has the lowest at -63.87%. This indicates that Kerala Ayurveda's 1-year return is significantly worse than that of Astonea Labs. Additionally, the six-month return is negative for Kerala Ayurveda, Lyka Labs, and Oxygenta Pharma.

How big is Kerala Ayurveda?

As of 31st August, Kerala Ayurveda Ltd has a market capitalization of 234.00 Cr and reported Net Sales of 135.73 Cr, with a Net Profit loss of 26.53 Cr over the latest four quarters. Shareholder's Funds were 9.49 Cr and Total Assets were valued at 123.99 Cr as of March 2025.

As of 31st August, Kerala Ayurveda Ltd has a market capitalization of 234.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Kerala Ayurveda reported Net Sales of 135.73 Cr. However, the company experienced a Net Profit loss of 26.53 Cr during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, where Shareholder's Funds amounted to 9.49 Cr and Total Assets were valued at 123.99 Cr.

Should I buy, sell or hold Kerala Ayurveda Ltd?

When is the next results date for Kerala Ayurveda Ltd?

The next results date for Kerala Ayurveda Ltd is 12 August 2026.

The next results date for Kerala Ayurveda Ltd is scheduled for 12 August 2026.

Are Kerala Ayurveda Ltd latest results good or bad?

Kerala Ayurveda Ltd's latest results are concerning, showing a net loss of ₹7.76 crores in Q4 FY26, a 74.38% decline from the previous quarter, despite a 10.92% revenue growth. Rising operational costs and negative margins indicate significant financial challenges.

The latest results for Kerala Ayurveda Ltd indicate a challenging financial situation. In Q4 FY26, the company reported a net loss of ₹7.76 crores, which is a significant decline of 74.38% compared to the previous quarter and a 50.06% increase in losses year-on-year. While revenue grew by 10.92% year-on-year to ₹34.74 crores, this growth has not translated into profitability, as operational costs continue to rise sharply.<BR><BR>The operating margin, excluding other income, stood at -20.44%, showing only a slight improvement from -32.38% in the same quarter last year, but still reflecting serious operational issues. Additionally, employee costs have surged, consuming over half of the company's sales, which raises concerns about cost management and operational efficiency.<BR><BR>Overall, while there is some revenue growth, the persistent losses and deteriorating margins suggest that the company's financial health is quite poor, making the latest results more negative than positive.

How has been the historical performance of Kerala Ayurveda?

Kerala Ayurveda's historical performance has shown revenue growth from INR 58.90 crore in March 2019 to INR 120.33 crore in March 2025, but profitability has declined sharply, resulting in a net loss of INR -13.96 crore in March 2025. Despite positive cash flow from operations of INR 4.00 crore, the company faced significant challenges with an overall net cash outflow of INR -19.00 crore.

Answer:<BR>The historical performance of Kerala Ayurveda shows significant fluctuations over the years, particularly in revenue and profitability.<BR><BR>Breakdown:<BR>Kerala Ayurveda's net sales have shown a steady increase from INR 58.90 crore in March 2019 to INR 120.33 crore in March 2025. However, the total expenditure has also risen sharply, leading to an operating profit (PBDIT) that turned negative at INR -4.99 crore in March 2025, down from INR 8.83 crore in March 2024. This decline in profitability is reflected in the profit before tax, which fell to INR -12.24 crore in March 2025, compared to a profit of INR 0.66 crore in the previous year. Consequently, the profit after tax also dropped significantly to INR -13.96 crore in March 2025, indicating a challenging financial environment. The company's total assets decreased slightly to INR 123.99 crore in March 2025 from INR 128.47 crore in March 2024, while total liabilities also saw a decline to INR 123.99 crore from INR 128.47 crore. Cash flow from operating activities was positive at INR 4.00 crore in March 2025, but the overall net cash outflow was INR -19.00 crore, reflecting the company's struggles in managing its cash position effectively.

Is Kerala Ayurveda technically bullish or bearish?

As of 29 October 2025, the market trend is neutral with mixed signals, showing a shift from mildly bullish to sideways, as weekly indicators are mostly bearish while monthly indicators remain bullish.

As of 29 October 2025, the technical trend has changed from mildly bullish to sideways. The current technical stance is neutral, with mixed signals across different time frames. The weekly MACD is mildly bearish, while the monthly MACD remains bullish, indicating a divergence in momentum. The weekly Bollinger Bands are also mildly bearish, contrasting with the monthly Bollinger Bands which are mildly bullish. Moving averages on the daily chart show a mildly bullish stance, but the KST and Dow Theory are both bearish on the weekly and monthly charts. Overall, the indicators suggest a lack of clear direction, reinforcing the sideways trend.

Is Kerala Ayurveda overvalued or undervalued?

As of May 27, 2025, Kerala Ayurveda is considered risky and overvalued with a PE ratio of -37.04 and an EV to EBITDA of -122.35, significantly lagging behind peers like Sun Pharma and Cipla, despite a strong 1-year stock return of 55.01% compared to the Sensex's 7.58%.

As of 27 May 2025, the valuation grade for Kerala Ayurveda has moved from very expensive to risky, indicating a significant shift in its market perception. The company appears to be overvalued, with a PE ratio of -37.04, an EV to EBITDA ratio of -122.35, and a Price to Book Value of 57.37. These ratios suggest that the company's earnings and asset valuations are not aligned with its current market price.<BR><BR>In comparison to its peers, Kerala Ayurveda's metrics are starkly unfavorable. For instance, Sun Pharma has a PE ratio of 35.25 and an EV to EBITDA of 24.91, while Cipla shows a PE of 22.99 and an EV to EBITDA of 15.93, both indicating more robust valuations. The company's recent stock performance has outpaced the Sensex, with a 1-year return of 55.01% compared to the Sensex's 7.58%, but this does not mitigate its current overvaluation status.

Who are the top shareholders of the Kerala Ayurveda?

The top shareholders of Kerala Ayurveda are Katra Holdings Ltd with 53.97%, followed by individual investors at 32.23%, and Porinju Veliyath as the largest public shareholder at 5.18%. Mutual funds hold 0.02%, and there are no foreign institutional investors.

The top shareholders of Kerala Ayurveda include Katra Holdings Ltd, which holds the largest share at 53.97%. This is followed by individual investors, who collectively own 32.23% of the company. The highest public shareholder is Porinju Veliyath, with a holding of 5.18%. Additionally, there is a small percentage of shares held by mutual funds, specifically 0.02%, and no foreign institutional investors (FIIs) currently hold shares in the company.

Has Kerala Ayurveda declared dividend?

No Dividend History Available